Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ACM Global Relocates to Expanded Lab Facilities in Europe

Published: Friday, November 30, 2012
Last Updated: Thursday, November 29, 2012
Bookmark and Share
Global Central Lab relocates European headquarters to new facility in York.

ACM Global Central Lab has announced that it has relocated its laboratory facilities in York, England.

The move to a larger facility is in response to growing client demand for ACM Global’s clinical trials testing services throughout Europe, including Western and Eastern Europe, as well as South Africa and the Middle East.

The new facility offers 14,500 square feet of laboratory and office space, nearly twice the size of ACM Global’s previous facility in York, and accommodates ACM Global’s expanding laboratory operations, as well as its growing staff of data analysts, project managers and quality assurance specialists.

“Our new facility enables us to continue our growth in the European market and to expand the menu of clinical trials testing services we offer our clients,” said Jerry Boxall, managing director, Europe at ACM Global Central Laboratory.

Boxall continued, “We are excited with the prospects offered by our new facility, which has been purpose-built to optimize our laboratory processes. The additional space enhances our ability to continue to meet the needs of our clients with high-quality laboratory services, while positioning us to take advantage of new opportunities in the market.”

“Expansion of our European laboratory hub represents a significant investment by our company, driven by our growth over the last several years,” said Angela J. Panzarella, president of ACM Medical Laboratory, Incorporated, the parent company of ACM Global Central Laboratory.

Panzarella continued, “We have enjoyed robust growth in our European and global business, and the new facility represents our commitment to the region and to continuous improvement of the services we offer our clients.”

To celebrate its new laboratory location, ACM Global will host a grand opening and ribbon-cutting event on Thursday, Jan. 17, 2013 at the new facility, located at 23 Hospital Fields Road in York.

Current and prospective clients are invited to attend the day-long event, which will include tours of the facility, a workshop and an evening reception.

For questions regarding the relocation or to attend the grand opening, please visit www.acmgloballab.com/YorkFAQ.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ACM Global Officially Opens New Shanghai Lab Facility
Newest lab facility leverages local expertise to extend ACM Global’s robust capabilities across China and surrounding regions.
Thursday, September 11, 2014
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!